There are currently 96 clinical trials in Wilmington, North Carolina looking for participants to engage in research studies. Trials are conducted at various facilities, including PMG Research of Wilmington, LLC, GSK Investigational Site, PMG Research of Wilmington and New Hanover Regional Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Identify and Characterise Patients With Chronic Kidney Disease and Proteinuria
NCT05967806
Recruiting
The purpose of the D4325C00007 study is to identify and characterise patients with known or newly diagnosed CKD for possible participation in future renal clinical studies and to obtain an overview on current treatment choices for this patient group in different regions.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
03/14/2024
Locations: Research Site, Wilmington, North Carolina
Conditions: Renal Disease
Register for Updates
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
NCT03911700
Recruiting
This trial is being conducted to evaluate the efficacy of Phasix™ Mesh implantation at the time of midline fascial closure compared to primary suture closure in preventing a subsequent incisional hernia in subjects at risk for incisional hernia after open midline laparotomy surgery.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: New Hanover Regional Medical Center, Wilmington, North Carolina
Conditions: Open Midline Laparotomy
Register for Updates
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
NCT05803421
Recruiting
The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Accellacare - Wilmington - 1917 Tradd Court, Wilmington, North Carolina
Conditions: Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
Register for Updates
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants
NCT05584202
Recruiting
The study will evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273.214 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in infants aged 12 weeks to < 6 months.
Gender:
All
Ages:
Between 2 months and 6 months
Trial Updated:
03/12/2024
Locations: Velocity Clinical Research (Hastings - Nebraska) - PPDS, Wilmington, North Carolina
Conditions: SARS-CoV-2
Register for Updates
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
03/11/2024
Locations: Research Site, Wilmington, North Carolina
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Register for Updates
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05767021
Recruiting
A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/07/2024
Locations: Wilmington Medical Research, Wilmington, North Carolina
Conditions: Ulcerative Colitis, Ulcerative Colitis Chronic
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
NCT06003426
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Gender:
All
Ages:
40 years and above
Trial Updated:
03/06/2024
Locations: Accellacare US Inc. of Wilmington, Wilmington, North Carolina
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring
NCT05739123
Recruiting
The Relugolix Pregnancy Registry is a prospective, observational cohort study designed to evaluate the association between relugolix-containing therapy exposure during pregnancy and subsequent maternal, fetal, and infant outcomes. Data will be collected from enrolled pregnant women and the healthcare providers (HCPs) involved in their care or the care of their infants, if applicable.
Gender:
Female
Ages:
0 years and above
Trial Updated:
03/06/2024
Locations: PPD, Wilmington, North Carolina
Conditions: Pregnancy Related, Pregnancy Complications, Pregnancy, High Risk
Register for Updates
Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
NCT04308590
Recruiting
This is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, and safety of relacorilant to treat hypercortisolism in patients with cortisol-secreting adrenal adenoma or hyperplasia associated with diabetes mellitus/ impaired glucose tolerance and/or uncontrolled systolic hypertension.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/05/2024
Locations: Site 01, Wilmington, North Carolina
Conditions: Hypercortisolism
Register for Updates
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
NCT04846959
Recruiting
The objective of this registry is to compare outcomes of risankizumab-exposed pregnancies with those of pregnancies that were not exposed to risankizumab among women with plaque psoriasis, psoriatic arthritis (PsA), Crohn's disease (CD), or other conditions for which risankizumab is an FDA-approved treatment. The registry is designed to estimate the association between risankizumab and maternal, fetal, and infant outcomes by comparing the prevalence rates of these outcomes in the exposed and une... Read More
Gender:
Female
Ages:
All
Trial Updated:
03/05/2024
Locations: PPD Development, LP /ID# 232134, Wilmington, North Carolina
Conditions: Plaque Psoriasis, Psoriatic Arthritis, Crohn Disease, Other Conditions for Which Risankizumab is an FDA-approved Treatment
Register for Updates
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
NCT05202509
Recruiting
This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD) who are not adequately controlled despite maximally tolerated lipid-lowering therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/01/2024
Locations: Wilmington Health Associates, Wilmington, North Carolina
Conditions: Atherosclerotic Cardiovascular Disease
Register for Updates
Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
NCT05772169
Recruiting
This is a Phase 4 study with 2 parts: Part 1 (Prevalence Phase) is non-interventional and will assess the prevalence of hypercortisolism in a population with difficult to control type 2 diabetes (T2D) (hemoglobin A1c ≥7.5%) despite receiving standard-of-care therapies. Part 2 (Treatment Phase) is a randomized, prospective, placebo-controlled, double-blind multi-center trial that will assess the safety and efficacy of mifepristone treatment in patients with hypercortisolism who have difficult to... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/22/2024
Locations: Site 059, Wilmington, North Carolina
Conditions: Hypercortisolism, Diabetes Mellitus, Type 2
Register for Updates